[go: up one dir, main page]

FR2893841B1 - DEPIGMENTING PHARMACEUTICAL COMPOSITION COMPRISING N- (2 - ((3- (4-BROMOPHENYL) -2-PROPENYL) AMINO) ETHYL) -5-ISOQUINOLINESULFONAMIDE (H89) - Google Patents

DEPIGMENTING PHARMACEUTICAL COMPOSITION COMPRISING N- (2 - ((3- (4-BROMOPHENYL) -2-PROPENYL) AMINO) ETHYL) -5-ISOQUINOLINESULFONAMIDE (H89)

Info

Publication number
FR2893841B1
FR2893841B1 FR0511977A FR0511977A FR2893841B1 FR 2893841 B1 FR2893841 B1 FR 2893841B1 FR 0511977 A FR0511977 A FR 0511977A FR 0511977 A FR0511977 A FR 0511977A FR 2893841 B1 FR2893841 B1 FR 2893841B1
Authority
FR
France
Prior art keywords
isoquinolinesulfonamide
depigmenting
bromophenyl
propenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0511977A
Other languages
French (fr)
Other versions
FR2893841A1 (en
Inventor
Corine Bertolotto
Robert Ballotti
Flavie Luciani
Mehdi Khaled
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires D'anjou Fr
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Galderma Research and Development SNC filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR0511977A priority Critical patent/FR2893841B1/en
Priority to PCT/EP2006/068772 priority patent/WO2007060182A1/en
Priority to ARP060105185A priority patent/AR057933A1/en
Publication of FR2893841A1 publication Critical patent/FR2893841A1/en
Application granted granted Critical
Publication of FR2893841B1 publication Critical patent/FR2893841B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
FR0511977A 2005-11-25 2005-11-25 DEPIGMENTING PHARMACEUTICAL COMPOSITION COMPRISING N- (2 - ((3- (4-BROMOPHENYL) -2-PROPENYL) AMINO) ETHYL) -5-ISOQUINOLINESULFONAMIDE (H89) Expired - Lifetime FR2893841B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0511977A FR2893841B1 (en) 2005-11-25 2005-11-25 DEPIGMENTING PHARMACEUTICAL COMPOSITION COMPRISING N- (2 - ((3- (4-BROMOPHENYL) -2-PROPENYL) AMINO) ETHYL) -5-ISOQUINOLINESULFONAMIDE (H89)
PCT/EP2006/068772 WO2007060182A1 (en) 2005-11-25 2006-11-22 Use of n-(2-((3-(4-bromophenyl)-2-propenyl)amino)ethyl)-5-isoquinolinesulfonamide (h89) in a depigmenting pharmaceutical composition
ARP060105185A AR057933A1 (en) 2005-11-25 2006-11-24 DEPIGMENTING PHARMACEUTICAL COMPOSITION INCLUDING N- (2 - ((3- (4- BROMOFENIL) - 2- PROPENIL) AMINO) ETIL) -5- ISOQUINOLINSULFONAMIDE (H89)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0511977A FR2893841B1 (en) 2005-11-25 2005-11-25 DEPIGMENTING PHARMACEUTICAL COMPOSITION COMPRISING N- (2 - ((3- (4-BROMOPHENYL) -2-PROPENYL) AMINO) ETHYL) -5-ISOQUINOLINESULFONAMIDE (H89)

Publications (2)

Publication Number Publication Date
FR2893841A1 FR2893841A1 (en) 2007-06-01
FR2893841B1 true FR2893841B1 (en) 2014-04-25

Family

ID=36934164

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0511977A Expired - Lifetime FR2893841B1 (en) 2005-11-25 2005-11-25 DEPIGMENTING PHARMACEUTICAL COMPOSITION COMPRISING N- (2 - ((3- (4-BROMOPHENYL) -2-PROPENYL) AMINO) ETHYL) -5-ISOQUINOLINESULFONAMIDE (H89)

Country Status (3)

Country Link
AR (1) AR057933A1 (en)
FR (1) FR2893841B1 (en)
WO (1) WO2007060182A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112903657B (en) * 2021-01-28 2022-06-24 中山大学 A kind of surface-enhanced Raman spectroscopy detection method of melamine and formaldehyde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835252B1 (en) * 2002-01-25 2005-08-05 Seppic Sa USE OF A PROTEIN KINASE A INACTIFYING COMPOUND IN A COMPOSITION CONTAINING A COSMETICALLY ACCEPTABLE MEDIUM FOR LAMINATING THE SKIN
US7256200B2 (en) * 2003-02-10 2007-08-14 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Method and composition for potentiating an oplate analgesic

Also Published As

Publication number Publication date
AR057933A1 (en) 2007-12-26
FR2893841A1 (en) 2007-06-01
WO2007060182A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
FR14C0069I2 (en) PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE
CY2017038I1 (en) NEW PHARMACEUTICAL SYSTEMS CONTAINS 4- (4- (3- (4-CHLORO-3-TRIFTORMENTHYL-PHENIL) -RIDO) -3-FTHORO-PHENOXY-PYRIDIN-2-CARBOXYLIC
IL225167A (en) (p-methoxy)phenyl-sulfonamide, n-(i-butyl), n-[(2r)-hydroxy-(3r)-benzyl-propyl] derivatives
EP1425019A4 (en) PHARMACEUTICAL COMPOSITION
DK1799633T3 (en) Crystal forms of (-) - (1R, 2R) -3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol hydrochloride for use as active ingredient in pharmaceutical compositions
FR2881652B1 (en) MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
FR2892937B1 (en) MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
DK1651621T3 (en) 2- (Quinoxaline-5-ylsulfonylamino) benzamide compounds as CCK2 modulators
IL185035A0 (en) Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
IL186308A (en) Pharmaceutical formulation comprising metformin hydrochloride and pioglitazone hydrochloride
DK1484970T3 (en) Benzamides and compositions comprising benzamides for use as fungicides
DK1725218T3 (en) Pharmaceutical composition comprising pimobendan
EP1987825A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR PHOSPHATE
DK1587478T3 (en) PHARMACEUTICAL COMPOSITION
EP1970076A4 (en) PHARMACEUTICAL COMPOSITION FOR UNIGEAL APPLICATION
EP1747004A4 (en) PHARMACEUTICAL COMPOSITIONS FOR METABOLIC INSUFFICIENCIES
NO20053119D0 (en) Pharmaceutical intestinal composition with fentanyl for intranasal administration.
NO20052952D0 (en) Pharmaceutical composition comprising microparticles
PL1771069T3 (en) N-(2-(hydroxymethyl) phenyl)-1h-pyrazole-4-carboxamide derivatives and related compounds as microbicidal active ingredients for phyto-protection and the protection of materials
DK3072507T3 (en) PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICODE SUBSTITUTION THERAPY
DK1643976T3 (en) Pharmaceutical formulation comprising levothyroxine sodium
JP2008510815A5 (en) Oxazolo-naphthyl acid as a plasminogen activator inhibitor type 1 (PAI-1) modulator
ITPN20050014A1 (en) "PERFECTED LEVELER FEET"
EP1819323A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-NUCLEATION AGENT
IS7766A (en) N- (3-methoxy-5-methylpyrazin-2-yl) -2- (4- [1,3,4-oxadiazol-2-yl] phenyl) pyridine-3-sulfonamide as an anticancer drug

Legal Events

Date Code Title Description
TP Transmission of property
RN Application for restoration

Effective date: 20130903

FC Decision of inpi director general to approve request for restoration

Effective date: 20140211

ST Notification of lapse

Effective date: 20140402

FC Decision of inpi director general to approve request for restoration

Effective date: 20140415

TQ Partial transmission of property

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20140530

Owner name: LES LABORATOIRES D'ANJOU, FR

Effective date: 20140530

PLFP Fee payment

Year of fee payment: 11

CA Change of address

Effective date: 20160831

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20